P472: Efficacy of intravenous ustekinumab re-induction in patients with Crohn’s disease with a loss of response
ECCO '19 Copenhagen
2019
P473: Cumulative histological inflammation predicts colorectal neoplasia in ulcerative colitis
ECCO '19 Copenhagen
2019
P474: Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland
ECCO '19 Copenhagen
2019
P475: Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy
ECCO '19 Copenhagen
2019
P476: Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis
ECCO '19 Copenhagen
2019
P477: Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study
ECCO '19 Copenhagen
2019
P478: Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
ECCO '19 Copenhagen
2019
P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD
ECCO '19 Copenhagen
2019
P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre
ECCO '19 Copenhagen
2019
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
ECCO '19 Copenhagen
2019
P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study
ECCO '19 Copenhagen
2019
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
ECCO '19 Copenhagen
2019
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
ECCO '19 Copenhagen
2019
P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling
ECCO '19 Copenhagen
2019